任何中国企业不得向美进行新的投资
绝不让中国制造向美回流
中国政府停止审批任何赴美投资新项目
版主： Softfist
x1
x1
-
cockroachusmle（蟑蝈蟧）
- 知名作家
- 帖子互动： 317
- 帖子： 1171
- 注册时间： 2023年 11月 14日 23:37
-
hongwei1124
- 论坛点评
- 帖子互动： 112
- 帖子： 2616
- 注册时间： 2022年 7月 27日 14:16
-
Scraper
- 论坛元老
Scraper 的博客 - 帖子互动： 834
- 帖子： 22924
- 注册时间： 2022年 7月 26日 15:14
#18 Re: 中国政府停止审批任何赴美投资新项目
美国有光刻胶中的光源，算是核心技术
但是美国自己没有欧洲日韩台的帮助，绝对不可能造出来光刻机
目前，工业界三足鼎立，没有谁有绝对优势
美国的优势是芯片大体上能掌控
最大劣势是基础工业一坨狗屎，
现在造船业产能是中国的230分之一
如果美国能维持一个以上的代差，一击必杀，那美国没问题
只要没有代差，按照生产能力打持久战，
铲逼吊打全世界总和乘以2轻轻松松
此生无悔入华夏，家住加利福利亚
#19 Re: 中国政府停止审批任何赴美投资新项目
US-based pharmaceutical companies are increasingly licensing drugs from Chinese firms, with deals rising significantly in recent years, including those for oncology and other therapeutic areas.
Here's a more detailed breakdown:
Rising Trend:
U.S. companies are actively seeking out and licensing drugs developed in China, with the number of deals and the total value of these deals increasing substantially.
Motivations:
Cost-Effectiveness: Chinese biotechs offer a potentially cheaper alternative for acquiring new drug assets.
Innovation: China's biotech sector is rapidly growing, and companies are developing innovative drugs, including those in oncology.
Geopolitical Considerations: Despite some geopolitical tensions, the trend of licensing deals continues.
Examples of Deals:
Merck signed a licensing agreement with Jiangsu Hengrui Pharmaceuticals for a heart disease drug.
Bristol Myers Squibb licensed a HER3/EGFR bispecific antibody-drug conjugate (ADC) product from Biokin Pharma.
AstraZeneca licensed a small molecule GLP-1 receptor agonist from Eccogene.
BioNTech reached a licensing and cooperation agreement with Duality Bio for two ADC pipeline assets.
Here's a more detailed breakdown:
Rising Trend:
U.S. companies are actively seeking out and licensing drugs developed in China, with the number of deals and the total value of these deals increasing substantially.
Motivations:
Cost-Effectiveness: Chinese biotechs offer a potentially cheaper alternative for acquiring new drug assets.
Innovation: China's biotech sector is rapidly growing, and companies are developing innovative drugs, including those in oncology.
Geopolitical Considerations: Despite some geopolitical tensions, the trend of licensing deals continues.
Examples of Deals:
Merck signed a licensing agreement with Jiangsu Hengrui Pharmaceuticals for a heart disease drug.
Bristol Myers Squibb licensed a HER3/EGFR bispecific antibody-drug conjugate (ADC) product from Biokin Pharma.
AstraZeneca licensed a small molecule GLP-1 receptor agonist from Eccogene.
BioNTech reached a licensing and cooperation agreement with Duality Bio for two ADC pipeline assets.